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Retroviruses consume cellular deoxynucleoside triphosphates (dNTPs) to convert their RNA genomes
into proviral DNA through reverse transcription. While all retroviruses replicate in dividing cells,
lentiviruses uniquely replicate in nondividing cells such as macrophages. Importantly, dNTP levels in
nondividing cells are extremely low, compared to dividing cells. Indeed, a recently discovered anti-HIV/
SIV restriction factor, SAMHD1, which is a dNTP triphosphohydrolase, is responsible for the limited
dNTP pool of nondividing cells. Lentiviral reverse transcriptases (RT) uniquely stay functional even at
the low dNTP concentrations in nondividing cells. Interestingly, Vpx of HIV-2/SIVsm proteosomally
degrades SAMHD1, which elevates cellular dNTP pools and accelerates lentiviral replication in
nondividing cells. These Vpx-encoding lentiviruses rapidly replicate in nondividing cells by encoding
both highly functional RTs and Vpx. Here, we discuss a series of mechanistic and virological studies that
have contributed to conceptually linking cellular dNTP levels and the adaptation of lentiviral replication
in nondividing cells.
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All retroviruses, as well as retrotransposons, undergo a unique
DNA synthesis process called reverse transcription, which converts
single stranded RNA genomes into double stranded DNA. This
process is catalyzed by virally encoded DNA polymerases, reverse
transcriptases (RT) (reviewed in Hu and Hughes, 2012; Saraﬁanos
et al., 2009). Unlike cellular DNA polymerases, which synthesize
DNA from DNA templates, RTs can execute DNA polymerization
from RNA templates as well. RTs also harbor RNaseH activity, whichll rights reserved.
. Kim).can degrade RNA templates annealed to the newly synthesized
DNA. This activity enables RTs to undergo strand transfer and
recombination (Berkhout et al., 1995; Levy et al., 2004; Negroni
and Buc, 2000; Song et al., 2008; Zhang et al., 2000; Zhuang et al.,
2002). RTs also use small RNAs (tRNAs and the polypurine tract
RNAs) as primers to initiate ﬁrst and second strand DNA synthesis,
which are also removed by RNaseH activity (Huber and Richardson,
1990; Smith et al., 1999; Wohrl and Moelling, 1990; Wu et al.,
1999). All RTs utilize dNTPs as substrates for DNA polymerization,
and these dNTP substrates are provided by the infected cells. HIV-1
RT is the most well-characterized RT biochemically, structurally,
and pharmacologically. This is due to it being one of the key viral
proteins targeted by multiple pharmacological agents for the
treatment of HIV-1 infected patients.
Fig. 1. Cellular dNTP concentrations of human primary cells, human cancer cells
and transformed cell lines: Red asterisks: The dNTP concentration difference
between primary human macrophages and activated PBMCs. Blue asterisks: Effect
of dN treatment on cellular dNTP concentrations in primary human lung
ﬁbroblasts. A549: human adenocarcinoma alveolar basal epithelial cell line,
PANC1: human pancreas epithelioid carcinoma cell line, CHME5: transformed
human microglia cell line, 293FT: transformed human embryonic kidney cell line.
This ﬁgure was prepared by modifying the data previously presented (Jackson
et al., 1980).
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the truncated p51 subunit. The p66 monomer harbors two enzy-
matically functional domains, a DNA polymerase domain at the
N-terminus and an RNaseH domain at the C-terminal region (Huang
et al., 1998). The DNA polymerase domain of the p66 monomer
displays a molecular shape known as the right hand model that is
commonly found in many DNA polymerases. The DNA polymerase
active site is surrounded by three subdomains: the ﬁngers, palm
and thumb domains which interact with template, dNTP substrate
and primer, respectively. Another well-characterized RT is from
Murine Leukemia Virus (MuLV). Unlike HIV-1 RT, MuLV RTworks as
a monomer, but still maintains a right hand model for its DNA
polymerase active site (Cote and Roth, 2008).
A structural study of the tertiary complex of HIV-1 RT (RT with
bound template, primer, and dNTP) revealed speciﬁc residues near
the binding pocket that interact with different chemical moieties of
the dNTP (Huang et al., 1998). Mechanistic and structural studies of
HIV-1 RT mutations that render viral resistance against nucleoside/
nucleotide RT inhibitors provided the molecular architecture of the
HIV-1 RT dNTP binding site. These RT inhibitors chemically mimic
dNTP substrates, but have an altered sugar moiety for chain
termination (reviewed in De Clercq, 2009). Three aspartic acid
residues (D110, D185, and D186) form a triad with two metals
coordinating with the three phosphates of the dNTP substrate during
phosphodiester bond formation between the alpha-phosphate of the
incoming dNTP and the 30 OH of the DNA primer (Huang et al., 1998;
Saraﬁanos et al., 1999, 2009). Other residues involved in interacting
with the dNTP such as Y115, A114, Q151 and K65 were also studied
for their functional roles in the enzymatic activities of HIV-1 RT
(Boyer and Hughes, 2000; Ehteshami et al., 2008; Harris et al., 1998;
McColl et al., 2008; Melikian et al., 2012; Weiss et al., 2002).Cellular dNTP levels
While ribonucleoside triphosphates (rNTPs) act as substrates
for RNA polymerization, as well as functioning as energy carriers
and substrates of numerous cellular kinases, the sole utility of
cellular dNTPs is for DNA synthesis. The steady-state level of
cellular dNTPs is tightly regulated primarily by the cell cycle, and
both biosynthesis and consumption of cellular dNTPs occurs
during G1/S and S phase (Bjursell and Skoog, 1980; Cohen et al.,
1983). Expression of enzymes involved in dNTP biosynthesis such
as ribonucleotide reductase (RNR) (Bjorklund et al., 1990;
Engstrom et al., 1985; Mann et al., 1988) and thymidine kinase
(TK) (Stewart et al., 1987) are elevated prior and during cellular
replication. Thus, rapidly dividing cells such as cancer cells and
transformed cell lines harbor much higher levels of cellular dNTPs
than normal cells due to a larger proportion of the cell population
going through S phase (Angus et al., 2002; Jackson et al., 1980;
Skoog and Bjursell, 1974). Indeed, an elevated cellular dNTP level
is considered a biochemical marker of transformed/cancerous
cells (Angus et al., 2002; Jackson et al., 1980; Skoog and
Bjursell, 1974; Traut, 1994) (Fig. 1). It had also been postulated
that dividing cells contain higher cellular dNTP pools than
nondividing cells. However, unlike primary human dividing cell
types, the actual dNTP concentrations of primary human termin-
ally differentiated/nondividing cells had not been measured,
mainly due to the lack of a sensitive dNTP assay. In 2004,
the dNTP concentrations of human terminally differentiated/
nondividing monocyte-derived macrophages were measured
using a highly sensitive HIV-1 reverse transcriptase (RT) based
dNTP assay (Diamond et al., 2004). Indeed, the dNTP concentra-
tion of human macrophages (20–40 nM) was 22–320-fold lower
than that of activated human peripheral blood mononuclear
cells (PBMCs) primarily composed of CD4þ T cells (2–5 mM)(Diamond et al., 2004; Kennedy et al., 2010) (Fig. 1). While the
dNTP concentration discrepancy between these two HIV-1 target
cell types was expected, the magnitude of the dNTP concentration
discrepancy raised a fundamental question: How can HIV-1
synthesize proviral DNA in macrophages harboring such a limited
dNTP substrate pool? One practical reference linking dNTP con-
centrations and DNA polymerization is polymerase chain reaction
(PCR). Indeed, the dNTP concentration normally included for PCR
is 250 mM. Thus, the dNTP concentrations found in human
macrophages are at least 5000 times lower than the dNTP
concentrations used in PCRs. It was unclear how HIV-1 RT was
able to synthesize proviral DNA in macrophages containing such
low dNTP substrate concentrations.Kinetic differences in dNTP utilization between reverse
transcriptases from lentiviruses and other retroviruses
RTs consume cellular dNTPs during reverse transcription, and thus
the rate of proviral DNA synthesis is kinetically dependent on the
cellular dNTP concentrations. It was predicted that RTs of lentiviruses
may have evolved to efﬁciently synthesize DNA even at low dNTP
concentrations in order to complete proviral DNA synthesis in
nondividing cells. RT proteins of other retroviruses, which replicate
exclusively in dividing cells with high dNTP concentrations, would
not have this evolutionary pressure. Indeed, lentiviral RTs such as
HIV-1, SIV and FIV can efﬁciently synthesize DNA at the low dNTP
concentrations found in macrophages (Banapour et al., 1991; Rogers
et al., 2002; Skasko et al., 2005), whereas oncoretroviral RTs such as
MuLV, AMV, FV and FeLV efﬁciently synthesize DNA only at the high
dNTP concentrations found in dividing cells (Diamond et al., 2004;
Santos-Velazquez and Kim, 2008; Skasko et al., 2005). Fig. 2 presents
the Km value difference between HIV-1 RT andMuLV RT with respect
to the concentration of human macrophages and activated PBMCs
which were determined by two independent dNTP assays (primer
extension based assay (15) and quantitative LC-MS/MS (33)). These
observations support the idea that lentiviruses may have evolved RTs




Fig. 2. Comparison of the Km values of HIV-1 RT and MuLV RT with respect to dNTP concentrations in primary human macrophages and T cell/PBMCs. The dNTP
concentrations of human macrophages (MDM) and activated T cells/PBMCs were determined by the primer-extension based assay (grey bars, (Diamond et al., 2004)) and
quantitative LC–MS/MS assay (black bars, (Kennedy et al., 2010)). The ranges of the RT Km values were marked by two longitudinal bars (red for HIV-1 RT and blue for
MuLV RT). This ﬁgure was prepared by modifying the data presented previously (Diamond et al., 2004; Kennedy et al., 2010; Skasko et al., 2005). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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in this target cell type.Mechanistic features of HIV-1 RT that contribute to efﬁcient
dNTP utilization
There are two possible mechanistic scenarios to improve dNTP
utilization: (1) tight dNTP binding afﬁnity and (2) rapid enzy-
matic catalysis. These potential enzymatic features were tested
for HIV-1 RT and MuLV RT by determining pre-steady state
kinetic values, Kd and kpol (Skasko et al., 2005). While both RTs
displayed very similar kpol values, HIV-1 RT showed 10–100
times tighter dNTP binding afﬁnity than MuLV RT (Skasko et al.,
2005). This suggests that HIV-1 may have evolved to tightly bind
dNTP substrates in order to execute efﬁcient proviral DNA synth-
esis in the poor dNTP pools found in macrophages. In contrast,
MuLV may not need an RT with tight dNTP binding afﬁnity as
this virus exclusively infects dividing cells containing abundant
dNTPs.Fig. 3. Models for the direct interaction between the side chain of HIV-1 RT Q151
residue and 30–OH of incoming dNTPs. This structural view of the active site of the
HIV-1 RT complex with dNTP and template/primer was adapted from a 1D RT-
based model previously reported (Weiss et al., 2002). This ﬁgure shows the
interaction between wild type residue Q151 (light green) or mutant residue N151
(orange) and the incoming dTTP (black for base and sugar and red for tripho-
sphate), base-paring with the template nucleotide (dark blue). Template (blue
line), primer (purple), and incoming dNTP are shown and the nearby R73 (gray)
residue is also marked. While the Q151 side chain makes a hydrogen bond with
the 30–OH (O3) of the incoming dTTP, the Q151N mutant residue has a shortened
R side chain and cannot interact with the sugar on the incoming dTTP. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)Structural features of HIV-1 RT contributing to the uniquely
tight dNTP binding afﬁnity
To determine the structural features of HIV-1 RT that contribute
to the high binding afﬁnity, the dNTP binding pocket of the HIV-1
RT ternary complex structure was compared with that of other DNA
polymerases (Huang et al., 1998). Interestingly, the Q151 residue
lies near the 30 OH of the incoming dNTP. This structural model
suggested that the side chain of the Q151 residue is able to form a
hydrogen bond with the 30 OH (O3) of the incoming dNTP substrate
(green in Fig. 3) (Weiss et al., 2002). It is likely that this residue may
be structurally involved in the tight dNTP binding of HIV-1 RT. This
was further examined by constructing a Q151N mutant which
harbors a side chain that is one methylene group shorter than the
wild type Q151 RT and thus cannot form a hydrogen bond with the
30 OH of the incoming dNTP substrate (orange in Fig. 3). It was
predicted that Q151N would have a reduced dNTP binding afﬁnity
(Kd), but would maintain a catalysis rate (kpol) similar to wild type
RT. This was conﬁrmed by pre-steady state kinetic analysisdemonstrating that the Q151N mutant showed a 120-fold higher
Kd value compared to wild type RT, but with the same wild type kpol
value (Weiss et al., 2002). Another dNTP binding mutant, V148I
which lies in close proximity to the Q151 residue, also reduced the
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Q151Nmutant (Operario et al., 2006). Both Q151 and V148 residues
are conserved among all lentiviral RT sequences. More importantly,
these two HIV-1 RT mutants with reduced dNTP binding afﬁnity
failed to synthesize DNA at the low dNTP concentrations found in
macrophages, but were still fully active at the dNTP concentrations
found in activated T cells (Operario et al., 2006), suggesting that
these two HIV-1 RT mutants kinetically mimic MuLV RT. Interest-
ingly, MuLV RT also encodes a Q190 residue, which appears to be
equivalent to the Q151 of HIV-1 RT. However, mutations in the
Q190 residue of MuLV RT more severely reduce the biochemical
activity of RT and viral infectivity than mutations in the Q151
residue of HIV-1 RT. Collectively, these biochemical studies support
the idea that HIV-1 RT may have evolved to gain a unique
interaction with the 30 OH of the incoming dNTP in order to execute
efﬁcient proviral DNA synthesis in macrophages harboring limited
dNTP pools.Interplay between dNTP binding of HIV-1 RT and viral
cell tropism
Virological implications of the unique biochemical features of
HIV-1 RT were investigated by employing the recent knowledge
about the large dNTP concentration discrepancy between the two
HIV-1 target cell types, activated CD4þ T cells and macrophages.
One central prediction is that, unlike wild type RT, the reduced
dNTP binding mutant RTs should fail to support proviral DNA
synthesis in macrophages due to limited dNTP pools, but should
be able to replicate in activated CD4þ T cells as well as any
dividing cells containing abundant dNTP pools. Indeed, while the
HIV-1 variant vectors containing Q151N or V148I mutant RTs
efﬁciently supported proviral DNA synthesis and transduction in
various dividing cell lines and primary human activated CD4þ T
cells, both completely failed to transduce primary human macro-
phages (Diamond et al., 2004; Jamburuthugoda et al., 2006).
Basically, the HIV-1 variants harboring the reduced dNTP binding
RT mutants behave like MuLV or other retroviruses that exclu-
sively replicate in dividing cells. This virological ﬁnding is also
consistent with the biochemical ﬁndings discussed above (Skasko
et al., 2005; Weiss et al., 2002). Collectively, in addition to the Env
protein (Hwang et al., 1991) and several viral accessory proteins
such as Vpr and Vpx (reviewed in Ayinde et al., 2010), the
mechanistic and structural features of reverse transcriptase also
contribute to retroviral cell tropism by supporting optimal
proviral DNA synthesis kinetics through the proper utilization of
the available cellular dNTPs. Furthermore, based on these bio-
chemical and virological ﬁndings (Diamond et al., 2004;
Jamburuthugoda et al., 2006; Skasko et al., 2005; Weiss et al.,
2002), it was hypothesized that other viruses containing DNA
polymerase mutants with reduced dNTP binding afﬁnity may
replicate exclusively in cell types harboring elevated dNTP pools
such as cancer cells. This was conﬁrmed by a series of adenovirus
polymerase variants that replicate preferentially in cancer cells
and also function as oncolytic viruses (Capella et al., 2012).Mechanistic interactions between SAMHD1, Vpx, and cellular
dNTP levels and the effects on retroviral replication
Unlike HIV-1, HIV-2 and various SIV strains encode an acces-
sory protein, Vpx, which was known to facilitate viral infection in
macrophages (Goujon et al., 2007; Sharova et al., 2008). A series of
recent studies revealed that Vpx counteracts a protein, SAM
domain and HD domain-containing protein 1 (SAMHD1), which
serves as an HIV restriction factor (Hrecka et al., 2011; Laguetteet al., 2011). Both enzymatic and structural studies reported that
the HD domain of SAMHD1 harbors dNTP triphosphohydrolase
activity, which is allosterically activated by dGTP, and acts to
directly decrease dNTP levels by hydrolyzing dNTPs into deox-
ynucleosides (dNs) and triphosphates (Goldstone et al., 2011;
Powell et al., 2011). Indeed, a recent work revealed that SAMHD1
is responsible for the limited cellular dNTP pools in macrophages.
The elevation of cellular dNTPs in macrophages, which was
induced by either SAMHD1 degradation mediated by Vpx (red
arrow in Fig. 4) or treatment with dNs, the precursors of dNTPs,
accelerates proviral DNA synthesis and viral infectivity in macro-
phages (Lahouassa et al., 2012). A follow-up study also reported a
highly coordinated and sequential interplay between SAMHD1
degradation, dNTP level elevation, and accelerated
HIV-1 proviral DNA synthesis kinetics, upon the treatment of
macrophages with Vpx (Kim et al., 2012). In addition, another
recent study reported that Vpx also enhances HIV-1 infection of
resting CD4þ T cells by degradation of SAMHD1 followed by an
increase in dNTP levels (Baldauf et al., 2012). Collectively, these
ﬁndings support that the extremely low cellular dNTP pool serves
as a myeloid cell-speciﬁc biochemical anti-lentiviral restriction
factor, which is maintained by SAMHD1 dNTP triphosphohydro-
lase activity. Interestingly, genetic alterations in SAMHD1 result
in a rare human genetic developmental disorder, Aicardi–
Goutieres syndrome (AGS), which mimics viral infection and
immune activation (Leshinsky-Silver et al., 2011; Rice et al.,
2009; Thiele et al., 2010). A recent study reported that CD14þ
monocytes from AGS patients are highly susceptible to HIV-1
infection, which is consistent with the idea that SAMHD1 restricts
HIV replication in myeloid cell types (Berger et al., 2011).
Summarized in Fig. 4 are the effects of Vpx on the cellular
dNTP concentration in macrophages and the Km values of HIV-1/
MuLV RTs. The Km values of the lentiviral RTs are signiﬁcantly
lower than RTs of the retroviruses that replicate only in dividing
cells. However, the dNTP concentrations found in macrophages
are still lower than the Km values of the lentiviral RTs, indicating
that, although the low Km values of RTs allows lentiviruses to be
able to synthesize proviral DNA at low dNTP concentrations (blue
arrow in Fig. 4), HIV-1 RT alone is still not sufﬁcient for achieving
maximal proviral DNA synthesis kinetics in macrophages. How-
ever, in the case of the lentiviruses encoding Vpx, the dNTP
concentration is elevated above the Km value of lentiviral RTs (red
arrow in Fig. 4) leading to accelerated reverse transcription
kinetics and more efﬁcient completion of proviral DNA synthesis
in macrophages (Kim et al., 2012). Therefore, Vpx and the
uniquely low Km values of RTs synergistically enhance the
replication efﬁciency of these lentiviruses in macrophages Fig. 5.Unexpected frequent incorporation of rNMPs during HIV-1
proviral DNA synthesis in macrophages
Unlike dNTPs, which are exclusively used for DNA synthesis,
cellular rNTPs are widely used for various key molecular and
biochemical functions in the cell. rNTPs serve as substrates of
cellular RNA polymerases and numerous cell signaling kinases.
They also act as energy carriers in the cell. Due to the versatility of
rNTPs, it was expected that even macrophages would harbor high
cellular rNTP concentrations. Indeed, LC–MS/MS analysis con-
ﬁrmed that human primary macrophages have high levels
of rNTPs (mM range), which are very similar to the levels found
in activated CD4þ T cells (Kennedy et al., 2010). This high rNTP
concentration in macrophages is consistent with the observation
that SAMHD1, which is responsible for the low dNTP pools in
macrophages, does not hydrolyze rNTPs (Goldstone et al., 2011).
HIV-1 RT Km




Fig. 4. Effect of Vpx on cellular dNTP concentrations with respect to the Km values of HIV-1 RT andMuLV RT. The concentrations of four dNTPs in primary human macrophages
treated with the virus like particles with or without Vpx protein as well as the dNTP concentrations of human primary activated PBMCs are presented (Lahouassa et al., 2012).
Blue arrow indicates the Km difference between HIV-1 RT and MuLV RT, while the red arrow indicates the elevation of dNTP concentration induced by the Vpx protein. The Km
value of HIV-1 RT (red bar) stays above the dNTP concentration of macrophages. However, the Vpx treatment increases the dNTP concentration above the Km value of HIV-1 RT
in macrophages. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. Model for the mechanistic interplay among cellular dNTPs, SAMHD1,
proviral DNA synthesis, and potential mutagenic consequences during HIV reverse
transcription in macrophages. RT enzyme kinetics is controlled by the availability
of cellular dNTPs, which signiﬁcantly varies between dividing CD4þ T cells and
macrophages. These kinetic disparities appears to be tightly regulated by cellular
(SAMHD1) and viral (Vpx) players. The extremely low abundance of canonical
dNTPs in macrophages can force RT to incorporate mutagenic non-canonical
cellular nucleotides such as rNTPs and dUTP, generating a potentially mutagenic
landscape in macrophages.
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high levels of rNTPs generate a much larger discrepancy between
dNTP and rNTP concentrations in macrophages, compared to
activated CD4þ T cells (Kennedy et al., 2010). This large concen-
tration disparity and the abundant rNTP pool may force HIV-1 RT
to incorporate ribonucleoside monophosphates (rNMPs) during
proviral DNA synthesis in macrophages, but not in activated
CD4þ T cells. Indeed, a series of biochemical simulations vali-
dated that HIV-1 RT can incorporate rNMPs during DNA synthesis,
but only using macrophage dNTP/rNTP concentrations (Kennedy
et al., 2010). This was further conﬁrmed by the use of rN chain
terminators (rNCTs) which are ribonucleosides lacking a 30 OH.rNCTs differ from dN chain terminators, such as AZT, in that rNCTs
have a 20 OH. Predictably, if HIV-1 incorporates rNMPs during
reverse transcription, rNCTs should inhibit HIV replication.
Indeed, treatment with rNCTs (i.e., rACT) efﬁciently inhibited
HIV-1 replication in macrophages, but not in activated CD4þ T
cells (Kennedy et al., 2010). This virological data supports that
HIV-1 incorporates rNMPs during reverse transcription in macro-
phages. A recent follow-up study reported that HIV-1 RT incor-
porates rNMPs at a rate of 1 in 150 nucleotides in macrophages,
which is approximately 40 times more frequent than the enzy-
matic incorporation of an incorrect dNTP by HIV-1 RT (Kennedy
et al., 2012).
However, the virological consequences of rNMP incorpora-
tion during reverse transcription remain to be tested. One clue
for this comes from long standing research about rNMP
incorporation by cellular DNA polymerases. It has been well
established that rNMPs embedded in DNA induce DNA poly-
merase pausing and mutation synthesis (Ji et al., 1994; Nick
McElhinny et al., 2010; Shen et al., 2012). Interestingly, most
organisms contain repair systems to speciﬁcally remove rNMPs
embedded in dsDNA. RNaseH2 is a key enzyme that initiates
the removal of rNMPs from dsDNA by making 50 end nicks at
rNMP sites (Rychlik et al., 2010). More interestingly, RNaseH2
is another gene that contributes to AGS when it is mutated
(Crow et al., 2006; Rice et al., 2007). Also, a recent study from
siRNA screening reported that RNaseH2 is involved in the HIV-
1 life-cycle, though its mechanism remains unclear (Genovesio
et al., 2011). Indeed, it was recently revealed that rNMPs
embedded in HIV-1 proviral DNA likely remain unrepaired in
macrophages, because of lower expression levels of RNaseH2 in
macrophages and delayed gap repair activity found in macrophages,
compared to activated CD4þ T cells (Kennedy et al., 2012).Unusually high dUTP concentration in macrophages acts as an
anti-parasitic cellular defense
Non-canonical dNTPs such as dUTP have been known as an
anti-parasitic defense that can induce lethal mutagenesis for
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DNA genome replication. Considering the extremely poor dNTP
pools in macrophages, it was reasoned that dUTP, which com-
petes against canonical cellular dTTP during DNA synthesis, can
serve as an effective weapon against pathogens in macrophages.
More importantly, LC–MS/MS analysis revealed an unusually high
concentration of dUTP in macrophages, compared to the cellular
dTTP concentration (Kennedy et al., 2011). In addition, a bio-
chemical simulation demonstrated that HIV-1 RT fails to distin-
guish between dTTP and dUTP during reverse transcription and
thus efﬁciently incorporated dUMP. Indeed dideoxyuridine (ddU),
which is a chain terminator of deoxyuridine (dU), effectively
inhibits HIV-1 replication in macrophages, but not in activated
CD4þ T cells (Kennedy et al., 2011). This study provides evidence
that HIV-1 may encounter much stronger antiviral pressure in
macrophages from the unusually high dUTP concentration, com-
pared to activated CD4þ T cells. Indeed, HIV-1 has evolved a
mechanism to counteract the potential viral genome error cata-
strophe induced by dUMP incorporation during reverse transcrip-
tion. Incorporated dUMPs are removed by cellular UNG2
packaged into the virion (Mansky et al., 2000; Priet et al., 2005).
Furthermore, cellular cytidine deaminases such as APOBEC3G are
capable of creating dUMP sites in proviral DNA, which can also
contribute to viral mutagenesis, though this effect is counteracted
by another viral accessory protein, Vif (Harris et al., 2003;
Mangeat et al., 2003; Marin et al., 2003; Yu et al., 2004; Zhang
et al., 2003). Throughout evolution, retroviruses encountered a
series of cellular pressures that can lead to viral genomic muta-
tions. The perfect balance of mutation rate and viral ﬁtness must
have been achieved to provide for viral escape without leading to
error catastrophe.Summary and perspectives
HIV reverse transcription and RT biochemistry are currently
being revisited, particularly due to the recent discovery of
SAMHD1, which regulates dNTP levels. Is it clear that while the
cell receptor and co-receptor recognition by retroviral envelope
proteins is a primary determinant of cell tropism (Hwang et al.,
1991), viruses must have evolved to overcome other cell type
speciﬁc metabolic discrepancies. Indeed, as illustrated in Fig. 1,
the scarcity of cellular dNTPs in macrophages, which is engi-
neered by the enzymatic activity of SAMHD1, is a clear example of
a metabolic bottleneck that HIV has to counteract during viral
infection (Goldstone et al., 2011; Hrecka et al., 2011; Laguette
et al., 2011; Lahouassa et al., 2012; Powell et al., 2011). In
addition, the poor dNTP availability in macrophages generates a
unique metabolic environment that promotes viral mutagenesis
induced by frequent rNMP and non-canonical dUMP incorpora-
tion (Kennedy et al., 2010, 2011, 2012). These observations
caused us to predict that macrophages may serve as a viral
reservoir that contributes to the unique viral genomic hypermut-
ability of HIV-1. Finally, unlike retroviruses, other large DNA
viruses such as herpes viruses and cytomegaloviruses also infect
macrophages and thus will encounter low dNTP pools during
replication. However, these DNA viruses are equipped with their
own dNTP biosynthesis machinery that consists of several
enzymes such as ribonucleotide reductase and thymidine kinase
(Leiden et al., 1980; Lembo and Brune, 2009). Possibly, these large
DNA viruses gained their own dNTP biosynthesis machineries
throughout their evolution to counteract the SAMHD1-induced
low dNTP availability in nondividing target cell types. Collec-
tively, SAMHD1 may be a primitive cellular defense tool that was
developed to effectively control the replication of dNTP-utilizing
pathogens, particularly in nondividing cell types that do notrequire cellular dNTPs due to lack of cellular chromosomal DNA
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